title: Augmenter of liver regeneration (ALR) restrains concanavalin A-induced hepatitis in mice.
abstract: Augmenter of liver regeneration (ALR), produced and released by hepatocytes, has cytoprotective and immunoregulatory effects on liver injury, and has been used in many experimental applications. However, little attention has been paid to the effects of ALR on concanavalin A (Con A)-induced hepatitis. The purpose of this paper is to explore the protective effect of ALR on Con A-induced hepatitis and elucidate potential mechanisms. We found that the ALR pretreatment evidently reduced the amount of ALT and AST in serum. In addition, pro-inflammatory cytokines, chemokines and iNOS were suppressed. ALR pretreatment also decreased CD4(+), CD8(+) T cell infiltration in liver. Besides, we observed that ALR pretreatment was capable of suppressing the activation of several signaling pathways in Con A-induced hepatitis. These findings suggest that ALR can obviously weaken Con A-induced hepatitis and ALR has some certain immune regulation function.
authors.affiliation: School of Life Science and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People's Republic of China; Liver Disease Key Laboratory, Center of Infectious Diseases, 458 Hospital, 801 Dongfengdong Road, Guangzhou 510600, People's Republic of China. Electronic address: mumao0102@gmail.com.
authors.forename: Mao
authors.initials: M
authors.lastname: Mu
authors.affiliation: Liver Disease Key Laboratory, Center of Infectious Diseases, 458 Hospital, 801 Dongfengdong Road, Guangzhou 510600, People's Republic of China. Electronic address: zhengwei-523@hotmail.com.
authors.forename: Zhenwei
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: School of Life Science and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People's Republic of China; Liver Disease Key Laboratory, Center of Infectious Diseases, 458 Hospital, 801 Dongfengdong Road, Guangzhou 510600, People's Republic of China. Electronic address: chengyidyt@163.com.
authors.forename: Yi
authors.initials: Y
authors.lastname: Cheng
authors.affiliation: Liver Disease Key Laboratory, Center of Infectious Diseases, 458 Hospital, 801 Dongfengdong Road, Guangzhou 510600, People's Republic of China. Electronic address: lgze68@163.com.
authors.forename: Guangze
authors.initials: G
authors.lastname: Liu
authors.affiliation: Liver Disease Key Laboratory, Center of Infectious Diseases, 458 Hospital, 801 Dongfengdong Road, Guangzhou 510600, People's Republic of China. Electronic address: 13631341977@163.com.
authors.forename: Xiusheng
authors.initials: X
authors.lastname: Chen
authors.affiliation: School of Life Science and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People's Republic of China. Electronic address: wuxin44771@163.com.
authors.forename: Xin
authors.initials: X
authors.lastname: Wu
authors.affiliation: Liver Disease Key Laboratory, Center of Infectious Diseases, 458 Hospital, 801 Dongfengdong Road, Guangzhou 510600, People's Republic of China. Electronic address: 1003550116@qq.com.
authors.forename: Caifang
authors.initials: C
authors.lastname: Zhuang
authors.affiliation: School of Life Science and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People's Republic of China. Electronic address: liubingying530@gmail.com.
authors.forename: Bingying
authors.initials: B
authors.lastname: Liu
authors.affiliation: Liver Disease Key Laboratory, Center of Infectious Diseases, 458 Hospital, 801 Dongfengdong Road, Guangzhou 510600, People's Republic of China. Electronic address: xiangping_kong@hotmail.com.
authors.forename: Xiangping
authors.initials: X
authors.lastname: Kong
authors.affiliation: School of Life Science and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People's Republic of China. Electronic address: yousong207@163.com.
authors.forename: Song
authors.initials: S
authors.lastname: You
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D002478:Cells, Cultured; D003208:Concanavalin A / Q000276:immunology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006520:Hepatitis, Animal / Q000188:drug therapy*; D018836:Inflammation Mediators / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D050862:Oxidoreductases Acting on Sulfur Group Donors / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D018836:Inflammation Mediators; D016328:NF-kappa B; D003208:Concanavalin A; D052247:Nitric Oxide Synthase Type II; D050862:Oxidoreductases Acting on Sulfur Group Donors; C551231:GFER protein, mouse; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D048049:Extracellular Signal-Regulated MAP Kinases
keywords: Augmenter of liver regeneration; Concanavalin A; Hepatitis; MAPK; NF-κB; T cell activation